אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 50 מ"ג ישראל - עברית - Ministry of Health

אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 50 מ"ג

novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.

אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 100 מ"ג ישראל - עברית - Ministry of Health

אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 100 מ"ג

novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.

אירינוטקאן זריקות 20 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אירינוטקאן זריקות 20 מ"ג/מ"ל

novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

וילאט 1000 ישראל - עברית - Ministry of Health

וילאט 1000

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

וילאט 500 ישראל - עברית - Ministry of Health

וילאט 500

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

אוקסליפלטין הוספירה 5 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אוקסליפלטין הוספירה 5 מ"ג/מ"ל

novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

אוקטאניין F 500 יח' בינל ישראל - עברית - Ministry of Health

אוקטאניין f 500 יח' בינל

dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

אוקטאניין F 1000 יח' בינל ישראל - עברית - Ministry of Health

אוקטאניין f 1000 יח' בינל

dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

אלבומינאטיב 40 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אלבומינאטיב 40 מ"ג/מ"ל

medigal ltd - albumin human 40 mg/ml - solution for injection - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

אלבומינאטיב 200 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אלבומינאטיב 200 מ"ג/מ"ל

medigal ltd - albumin human 200 mg/ml - solution for injection - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demontrated, and use of a colloid, such as albumin, is appropriate.the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.